Health ❯ Healthcare ❯ Regulatory Affairs

Drug Approval

European Medicines Agency FDA Anvisa Clinical Guidelines MHRA European Commission NICE Guidelines ANVISA Clinical Trials FDA Approval

Pfizer’s Oral Drug Shows Strong Phase 3 Results in Nonsegmental Vitiligo

The company says the medicine delivered meaningful facial and total-body repigmentation and will pursue regulatory approval for adult patients.

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

Donanemab Slows Alzheimer's Decline, New AAIC Data Show

EMA Committee Recommends Revoking Tavneos Authorization

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

EU Clears Sanofi’s Sarclisa for Subcutaneous Use With Portable Injector

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer

EMA Recommends Jascayd for Two Progressive Lung Fibrosis Conditions

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

BioMarin Says Voxzogo Raised Growth Rates in Children With Hypochondroplasia

Lilly Launches First Amyloid-Targeting Alzheimer’s Drug in India at Rs 91,688 a Dose

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

EU Drug Panel Backs Sanofi’s Cenrifki for Non‑Relapsing SPMS

HHS Chief Distances From FDA Replimune Denial as Oncologists Dispute Review

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Health Canada Approves Neffy, First Nasal Epinephrine for Anaphylaxis

UK Regulators Approve Single-Dose 7.2mg Wegovy Pen for Weekly Use

Multiple Indian Drugmakers Win U.S. Clearance to Sell Farxiga Generic

Acoramidis Shows Durable Survival Benefit in ATTR-CM Through 54 Months

FDA Approves Higher‑Dose Spinraza Regimen for Spinal Muscular Atrophy